-transparent.png){kind=logo}
A prospective randomized trial was undertaken to compare the efficacy and toxicity of murine antihunman T-cell monoclonal antibody (mcAb) therapy to that of horse antihuman thymocyte globulin (ATG) in the treatment of severe aplastic anemia (AA). Patients were randomized into one of the two treatment groups as well as to receive or not receive androgens. Median duration of aplasia prior to treatment was 1.5 and 2.2 months for the mcAb and ATG groups, respectively. One of 12 patients who received mcAb therapy had a partial response, whereas four of 13 patients receiving ATG had a complete or partial response. Of the 11 patients who failed mcAb treatment, six were subsequently treated with ATG and two improved. Ten of 13 patients who received ATG are surviving compared with seven of 12 patients who received mcAb. Toxicity of mcAb therapy was less than that of ATG. Future studies are needed to determine whether mcAbs known to be immunosuppressive are of benefit as therapy for patients with AA.
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
November 2009,
International journal of hematology,
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
May 2014,
Annals of hematology,
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
April 1982,
Scandinavian journal of haematology,
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
January 1986,
Sangre,
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
April 1988,
Blut,
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
August 1984,
Zhonghua nei ke za zhi,
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
August 2021,
European journal of haematology,
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
December 2023,
International journal of clinical pharmacology and therapeutics,
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
December 2021,
Hematology (Amsterdam, Netherlands),
K Doney, and
P Martin, and
R Storb, and
J Whitehead, and
A Smith, and
J A Hansen, and
F Appelbaum, and
C D Buckner, and
E D Thomas
September 2023,
Internal medicine (Tokyo, Japan),
